Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$18.30 +0.9%	$20.24	$10.21 ▼ $25.67	$4.37B	0.43	3.69 million shs	1.05 million shs
LJPC La Jolla Pharmaceutical		$5.73	$3.07 ▼ $6.24	$155.11M	2.39	158,476 shs	66,708 shs
LOGC LogicBio Therapeutics	$7.30 +0.7%	$2.06	$0.26 ▼ $3.77	$191.84M	2.06	168,718 shs	73,796 shs
NVAX Novavax	$6.80 +0.5%	$6.76	$5.01 ▼ $17.81	$1.10B	2.69	6.28 million shs	2.29 million shs
TARA Protara Therapeutics	$2.91 +4.5%	$3.18	$1.60 ▼ $10.48	$112.11M	1.35	796,678 shs	133,655 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	0.00%	+0.74%	-11.23%	-0.57%	+59.64%
LJPC La Jolla Pharmaceutical	0.00%	0.00%	0.00%	0.00%	0.00%
LOGC LogicBio Therapeutics	0.00%	+9.77%	+5.19%	+5.95%	+26.41%
NVAX Novavax	0.00%	+6.67%	-8.79%	+3.90%	-42.90%
TARA Protara Therapeutics	0.00%	+0.90%	-12.99%	-21.46%	+40.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	4.1602 of 5 stars	3.7	2.0	0.0	0.0	3.0	2.5	3.1
LJPC La Jolla Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LOGC LogicBio Therapeutics	1.4312 of 5 stars	0.0	4.0	0.0	4.7	0.6	0.8	0.6
NVAX Novavax	4.497 of 5 stars	3.1	2.0	0.0	4.7	1.3	0.8	3.1
TARA Protara Therapeutics	1.8027 of 5 stars	3.6	1.0	0.0	0.0	1.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	51.23% Upside
LJPC La Jolla Pharmaceutical	0.00	N/A	N/A	N/A
LOGC LogicBio Therapeutics	0.00	N/A	N/A	N/A
NVAX Novavax	2.29	Hold	$17.00	150.18% Upside
TARA Protara Therapeutics	3.14	Buy	$20.50	605.44% Upside

Current Analyst Ratings Breakdown

Latest ADMA, LJPC, LOGC, TARA, and NVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	NVAX Novavax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00
5/22/2025	TARA Protara Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$21.00
5/19/2025	NVAX Novavax	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/9/2025	NVAX Novavax	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$9.00 ➝ $7.00
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00
4/28/2025	TARA Protara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/16/2025	TARA Protara Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$12.00

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	10.24	$0.54 per share	33.77	$1.48 per share	12.36
LJPC La Jolla Pharmaceutical	$75.72M	0.00	N/A	7.95	($2.94) per share	0.00
LOGC LogicBio Therapeutics	$287M	0.67	N/A	N/A	$8.96 per share	0.81
NVAX Novavax	$682.16M	1.61	N/A	N/A	($3.89) per share	-1.75
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$4.77 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	21.52	26.51	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
LJPC La Jolla Pharmaceutical	$19.66M	$0.12	51.84	0.00	N/A	8.54%	-5.46%	4.00%	N/A
LOGC LogicBio Therapeutics	-$317M	-$5.79	N/A	∞	N/A	-141.03%	-81.98%	-52.13%	N/A
NVAX Novavax	-$187.50M	$2.65	2.56	84.94	0.06	38.14%	-115.51%	29.99%	8/14/2025 (Estimated)
TARA Protara Therapeutics	-$44.60M	-$1.72	N/A	N/A	N/A	N/A	-36.37%	-33.29%	8/5/2025 (Estimated)

Latest ADMA, LJPC, LOGC, TARA, and NVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1 2025	LOGC LogicBio Therapeutics	N/A	-$0.27	N/A	-$0.27	N/A	N/A
5/8/2025	Q1 2025	NVAX Novavax	$0.71	$2.93	+$2.22	$2.93	$204.08 million	$666.66 million
5/8/2025	Q1 2025	TARA Protara Therapeutics	-$0.47	-$0.29	+$0.18	-$0.29	N/A	N/A
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
LJPC La Jolla Pharmaceutical	N/A	N/A	N/A	N/A	N/A
LOGC LogicBio Therapeutics	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
LJPC La Jolla Pharmaceutical	N/A	4.02	3.52
LOGC LogicBio Therapeutics	N/A	31.60	31.60
NVAX Novavax	N/A	2.06	2.03
TARA Protara Therapeutics	N/A	18.03	18.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
LJPC La Jolla Pharmaceutical	97.06%
LOGC LogicBio Therapeutics	46.05%
NVAX Novavax	53.04%
TARA Protara Therapeutics	38.13%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.70%
LJPC La Jolla Pharmaceutical	36.30%
LOGC LogicBio Therapeutics	8.10%
NVAX Novavax	1.00%
TARA Protara Therapeutics	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	229.90 million	Optionable
LJPC La Jolla Pharmaceutical	61	24.94 million	15.89 million	Optionable
LOGC LogicBio Therapeutics	62	26.28 million	24.16 million	Optionable
NVAX Novavax	1,990	161.97 million	160.35 million	Optionable
TARA Protara Therapeutics	30	38.58 million	33.76 million	Optionable

ADMA, LJPC, LOGC, TARA, and NVAX Headlines

Recent News About These Companies

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - The Manila Times

July 2, 2025 | manilatimes.netM

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - Morningstar

July 2, 2025 | morningstar.comM

Protara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community - Nasdaq

July 2, 2025 | nasdaq.com

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

Protara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community

June 30, 2025 | quiverquant.comQ

Protara Therapeutics Announces Addition to the Russell 3000® Index

June 30, 2025 | globenewswire.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of "Buy" from Analysts

June 30, 2025 | americanbankingnews.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of "Buy" by Brokerages

June 30, 2025 | marketbeat.com

Protara Therapeutics, Inc. (TARA) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

RAPT Therapeutics Appoints Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. to Board of Directors

June 23, 2025 | quiverquant.comQ

Protara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025

June 14, 2025 | seekingalpha.com

Two Sigma Investments LP Cuts Stock Holdings in Protara Therapeutics, Inc. (NASDAQ:TARA)

June 14, 2025 | marketbeat.com

Analysts Set Expectations for TARA FY2026 Earnings

June 10, 2025 | marketbeat.com

Chutes & Ladders—Protara gears up for next steps with commercial pro

June 7, 2025 | fiercebiotech.comF

Protara Therapeutics, Inc. (NASDAQ:TARA) Position Increased by Bank of America Corp DE

June 7, 2025 | marketbeat.com

The Escalator: Digitas Health, Bristol Myers Squibb, Inizio Evoke and more

June 4, 2025 | mmm-online.comM

Protara Therapeutics names new Chief Commercial Officer

June 4, 2025 | investing.com

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

June 2, 2025 | globenewswire.com

Jones Trading Initiates Coverage of Protara Therapeutics (TARA) with Buy Recommendation

May 23, 2025 | msn.com

Richard Levy Spends US$64k On Protara Therapeutics Stock

May 22, 2025 | finance.yahoo.com

With 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backing

May 16, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA, LJPC, LOGC, TARA, and NVAX Company Descriptions

ADMA Biologics NASDAQ:ADMA

$18.30 +0.16 (+0.85%)

Closing price 07/3/2025 03:54 PM Eastern

Extended Trading

$18.33 +0.03 (+0.19%)

As of 06:03 AM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

La Jolla Pharmaceutical NASDAQ:LJPC

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.

LogicBio Therapeutics NASDAQ:LOGC

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Novavax NASDAQ:NVAX

$6.80 +0.04 (+0.52%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$6.80 0.00 (0.00%)

As of 06:19 AM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Protara Therapeutics NASDAQ:TARA

$2.91 +0.13 (+4.53%)

Closing price 07/3/2025 03:23 PM Eastern

Extended Trading

$2.88 -0.02 (-0.72%)

As of 04:00 AM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time